In this study, the bactericidal activity of antibacterial monomer MDPB (12-methacryloyloxydodecylpyridinium bromide) against Streptococcus mutans was tested by a rapid method for monitoring viability. To S. mutans culture containing fluorescence staining solution that distinguishes live from dead cells, MDPB was added at a concentration of 250, 100, 50, or 10 μg/ml. Bacterial cells were observed by fluorescence microscopy and the percentage of dead cells was calculated. After 10, 20, or 30 minutes' contact with MDPB, the live/dead ratio was measured by fluorometry and viable counts (CFU) determined by the conventional plating method. Viability staining revealed that MDPB exhibited significant bactericidal effects at 50 μg/ml or greater (ANOVA, Fisher' s PLSD test), and complete killing of the cells at 250 μg/ml of MDPB was demonstrated in conjunction with a plating method. The staining method thus provided a sensitive means to determine loss of viability, and indicated the strong killing effects of MDPB on S. mutans.

This study evaluated the clinical performance of a fluoride releasing restorative system (FL-Bond II & Beautifil II) in posterior restorations after 18-month placement. IRB forms were submitted with each patient approving by signing their acceptance. Seven Class I and 46 Class II restorations were placed by three clinicians in 38-patients. Each FL-Bond II & Beautifil II restoration was placed under rubber dam isolation according to manufacture's instruction. Clinical evaluation was assessed at baseline, 6 and 18-months using modified USPHS criteria. No post-operative sensitivity was reported in any restored tooth at each patient assessment. Only slight color change with some surface staining was noted. Slight marginal changes were observed in 12 of 53-restorations -seen as step irregularities when a sharp explorer was drawn across the tooth from the enamel toward the restoration interface. Utilizing USPHS evaluation criteria, the clinical performance of each (FL-Bond II & Beautifil II) posterior fluoride releasing system was clinically acceptable at 18-month.

No abstract

No abstract

No abstract